UCB.BR
Latest Trade
71.74EURChange
-0.06(-0.08%)Volume
275,435Today's Range
-
72.3052 Week Range
-
80.06As of on the Euronext Brussels ∙ Minimum 15 minute delay
Previous Close | 71.80 |
|---|---|
Open | 72.30 |
Volume | 275,435 |
3M AVG Volume | 8.05 |
Today's High | 72.30 |
Today's Low | 71.30 |
52 Week High | 80.06 |
52 Week Low | 62.26 |
Shares Out (MIL) | 188.37 |
Market Cap (MIL) | 13,965.51 |
Forward P/E | 15.78 |
Dividend (Yield %) | 1.15 |
UCB Presents Final Results from Phase II Study of Rozanolixizumab
UCB Announces Positive Results From The Phase 3 Active-Controlled Be Sure Study
UCB Announces Positive Results For Bimekizumab In Second Phase 3 Psoriasis Study
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Industry
Biotechnology & Drugs
Executive Leadership
Jean-Christophe Tellier
Chairman of the Executive Committee, Chief Executive Officer, Executive Director
Evelyn Diego du Monceau de Bergendal
Non-Executive Chair of the Board
Pierre L. Gurdjian
Independent Non-Executive Vice Chairman of the Board
Detlef Thielgen
Executive Vice President, Chief Financial Officer, Member of the Executive Committee
Charl van Zyl
Executive Vice President, Chief Operating Officer, Member of the Executive Committee
Price To Earnings (TTM) | 20.67 |
|---|---|
Price To Sales (TTM) | 2.98 |
Price To Book (MRQ) | 2.09 |
Price To Cash Flow (TTM) | 14.27 |
Total Debt To Equity (MRQ) | 21.41 |
LT Debt To Equity (MRQ) | 15.45 |
Return on Investment (TTM) | 8.31 |
Return on Equity (TTM) | 6.55 |
UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease.
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.
Belgian drugmaker UCB <UCB.BR> expects to invest about 1 billion pounds in Britain over the next five years, throwing its support behind the country's life sciences sector despite Brexit uncertainty.
* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY
* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
* FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION
* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN
* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF
* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS
* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS
* U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LABEL CHANGE FOR UCB’S CIMZIA®
* FY: REVENUE EUR 4.53 BILLION VERSUS EUR 4.43 BILLION IN REUTERS POLL, NET SALES EUR 4.18 BILLION VERSUS EUR 3.83 BILLION YEAR AGO
* UCB ADVANCES PSORIASIS PIPELINE WITH POSITIVE DATA AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD 2018)
* LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING Source text : http://bit.ly/2Fe7JUV Further company coverage: (Gdynia Newsroom)
* EUROPEAN MEDICINES AGENCY ACCEPTS FILING FOR EVENITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* BIMEKIZUMAB DEMONSTRATES IMPRESSIVE JOINT AND SKIN RESPONSES FOR PSORIATIC ARTHRITIS PATIENTS
* BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS
* Dermira and UCB agree to end collaboration agreement for Cimzia
* 9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.